Gamida Cell and Be The Match BioTherapies Announce Strategic Collaboration

Gamida Cell (Nasdaq:GMDA), a leading cellular and immune therapeutics company, and Be The Match BioTherapies, a subsidiary of the National Marrow Donor Program^®/Be The Match^® offering integrated platforms and software to manage the collection and delivery of cellular therapies, today announced a strategic collaboration to improve outcomes for patients undergoing allogeneic hematopoietic stem cell (bone marrow) transplantation.

As quoted in the press release:

Under the terms of the collaboration agreement, Gamida Cell and Be The Match BioTherapies will explore opportunities to work together across Gamida Cell’s ongoing clinical development program for NiCord, including the Phase 3 clinical study in patients with high-risk blood cancers. Be The Match BioTherapies has an extensive history of involvement in the delivery of cord blood units for transplant and broad access to cord blood banks globally.

The collaboration is expected to leverage a wide range of Be The Match BioTherapies’ research assets and services, including the Be The Match Registry^®, the largest in the world with more than 20 million potential donors, as well as personalized case management and logistics services.

“Gamida Cell’s work to bring a new therapeutic option to patients in need of a bone marrow transplant aligns with our core mission to help organizations deliver cellular therapies that save more lives and improve the quality of life for patients,” said Amy Ronneberg, president of Be The Match BioTherapies. “This collaboration is designed to leverage our expertise in cellular therapy to support the advancement of Gamida Cell’s clinical development and product delivery efforts.”

Click here to read the full press release.